4.2 Article

Epidemiology and risk factors for late infection in solid organ transplant recipients

Journal

TRANSPLANT INFECTIOUS DISEASE
Volume 13, Issue 6, Pages 598-607

Publisher

WILEY
DOI: 10.1111/j.1399-3062.2011.00646.x

Keywords

risk factors; late infection; epidemiology; outcome; solid organ transplantation

Funding

  1. Red Espanola de Investigacion en Patologia Infecciosa (REIPI) [RD06/0008/1013]
  2. Spanish Network for Research on Infection in Organ Transplantation (GESITRA)
  3. Centro de Investigacion Biomedica en Red en el Area tematica de Enfermedades Hepaticas y Digestivas (CIBERHED)

Ask authors/readers for more resources

Background Information concerning the risk factors and outcome of late infection (LI) after solid organ transplantation (SOT) still remains scarce. MethodsWe prospectively analyzed all patients undergoing SOT from July 2003 to March 2008, who survived the first 6 months after surgery and with a minimum 1-year follow-up. Risk factors associated with the development of bacterial and cytomegalovirus (CMV) LI and survival were identified. Results Overall, 942 SOT recipients (491 kidney, 280 liver, 65 heart, and 106 double transplants) were included. During the study period 147 patients (15.6%) developed 276 episodes of LI (incidence rate, 0.43 per 1000 transplantation-days). Bacteria were the most prevalent etiology (88.0%). Primary sources of infection included urinary tract (36.9%), intra-abdominal (16.7%), and sepsis without source (13.4%). Independent risk factors for late bacterial infection were: age (hazard ratio [ HR] [ per year] 1.0; 95% condence interval [ CI]: 1.0-1,0), female gender (HR 1.7; 95% CI: 1.1-2.6), anti-hepatitis C virus (HCV) positive serostatus (HR 1.8; 95% CI: 1.1-3.0), chronic allograft dysfunction (HR 3.2; 95% CI: 1.7-6.1), early CMVdisease (HR 2.2; 95% CI 1.2-4.1), and early bacterial infection (HR 2.5; 95% CI 1.6-3.8). The occurrence of chronic allograft dysfunction was an independent risk factor for late CMVdisease (HR 6.5; 95% CI: 1.7-24.6), whereas immunosuppression based on mammalian target of rapamycin inhibitors protected against the development of late CMVdisease (HR 0.3; 95% CI: 0.1-1.0). Cox model selected anti-HCVpositive serostatus (adjusted HR [ aHR] 2.67; 95% CI: 1.27-5.59), age (aHR [ per year] 1.06; 95% CI: 1.02-1.10), and the occurrence of LI (aHR 9.12; 95% CI: 3.90-21.33) as independent factors for mortality. Conclusions LI did not constitute an uncommon complication in our cohort, and patients at risk may benefit from close clinical monitoring.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available